Labrosse B, Morand-Joubert L, et al. 2006. Role of the envelope genetic context in the development of enfuvirtide resistance in human immu- nodeﬁciency virus type 1-infected patients. J Virol, 80:8807–19. Lalezari J, Henry K, et al. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med, 348:2175–85. Lazzarin A, Clotet B, et al. 2003. Efﬁcacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med, 348:2186–95. Lu J, Deeks S, et al. 2006. Rapid emergence of enfuvirtide resistance in HIV-1 infected patients:results of a clonal analysis. J Acquir Immune Deﬁc Syndr, 43:60–4. Lu J, Sista P, et al. 2004. Relative replicative ﬁtness of human immuno- deﬁciency virus type 1 mutants resistant to enfuvirtide T-20. J Virol, 78:4628–37. Matthews T, Salgo M, et al. 2004. Enfuvirtide:the ﬁrst therapy to inhibit the entry of HIV-1into host CD4 lymphocytes. Nat Rev Drug Discovery, 3:215–25. Melby T, Sista P, et al. 2006. Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptability to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses, 22:375–85. Moore J, Doms R. 2003. The entry of entry inhibitors:A fusion of science and medicine. Proc Natl Acad Sci USA, 100:10598–602. Negredo E, Bonjoch A, et al. 2005. Compromised immunologic recovery in treatment-experiences patients with HIV infection receiving both tenofovir disproxil fumarate and didanosine in the TORO studies. Clin Infect Dis, 41:901–5. Nelson M, Arasteh K, et al. 2005. Durable efﬁcacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1 infected patients in the T-20 versus optimized background only 1 and 2 clinical trials. J Acquir Immune Deﬁc Syndr, 40:404–12. Nunn A, Fonesca E, et al. 2007. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment. PLoS Med, 4:1804–17. Peuchant O, Capdepont S, et al. 2007. Primary resistance to enfuvirtide T20 in recently HIV-1 infected, antioretroviral-naive patients from the ANRS Aquitaine Cohort. Antivir Ther, 12:559–62. Enfuvirtide therapy Ray N, Harrison J, et al. 2007. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeﬁciency virus type 1 to other classes of entry inhibitors. J Virol, 81:3240–50. Reeves J, Fang-Hua L, et al. 2005. Enfuvirtide resistance mutations:impact on Human Immunodeﬁciency Virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol, 79:4991–9. Reeves J, Gallo S, et al. 2002. Sensitivity of HIV-1 to entry inhibitors cor- relates with envelope/coreceptor afﬁnity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA, 99:16249–54. Reynes J, Arasteh K, et al. 2007. TORO:Ninety-six week virologic and immunologic response and safety evaluation on enfuvirtide with and optimized background of antiretrovirals. AIDS Patient Care STDS, 21:533–43. Rimsky L, Shugars D, et al. 1998. Determinants of human immunodeﬁ- ciency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol, 72:986–93. Roman R, Gonzales D, et al. 2003. Uncommon mutations at residue posi- tions critical for enfuvirtide T-20 resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J Acquir Immune Deﬁc Syndr, 33:134–9. Villahermosa M, Perez-Alvarez L, et al. 2003. Primary resistance mutations to fusion inhibitors and polymorphisms in gp41 sequences of non-B subtypes and recombinants. AIDS, 17:1083–6. Wild C, Shugars D, et al. 1994. Peptides corresponding to a predictive alpha- helical domain of human immunodeﬁciency type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA, 91:9770–4. Wiznia A, Church J, et al. 2007. Safety and efﬁcacy for 48 weeks as part of an optimized antiretroviral regimen in pediatric Human Immunodeﬁciency Virus-1 patients. Pediatr Infect Dis J, 26:799–805. Youle M, Statsweski S, et al. 2006. Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experiences HIV- infected individuals: recent data and consensus recommendations. HIV Clin Trials, 7:86–96. Zhang X, Lin T, et al. 2007. Population pharmakokinetics of enfuvirtide in HIV-1 infected pediatric patients over 48 weeks of treatment. J Clin Pharmacol, 47:517–7. Therapeutics and Clinical Risk Management 2008:4(2) 439